BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34573332)

  • 21. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
    Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
    Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
    Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
    Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer.
    Wang J; He C; Gao P; Wang S; Lv R; Zhou H; Zhou Q; Zhang K; Sun J; Fan C; Ding G; Lan F
    Oncogene; 2020 Feb; 39(6):1335-1346. PubMed ID: 31636385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.
    Bian Z; Huang X; Chen Y; Meng J; Feng X; Zhang M; Zhang L; Zhou J; Liang C
    Int J Med Sci; 2021; 18(1):284-294. PubMed ID: 33390797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study.
    Abdelrahman AE; Arafa SA; Ahmed RA
    Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of RNA-binding protein SNRPA1 for prognosis in prostate cancer.
    Yuan P; Ling L; Gao X; Sun T; Miao J; Yuan X; Liu J; Wang Z; Liu B
    Aging (Albany NY); 2021 Jan; 13(2):2895-2911. PubMed ID: 33460399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioinformatics Analysis of GFAP as a Potential Key Regulator in Different Immune Phenotypes of Prostate Cancer.
    Yao W; Li X; Jia Z; Gu C; Jin Z; Wang J; Yuan B; Yang J
    Biomed Res Int; 2021; 2021():1466255. PubMed ID: 34222466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
    Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
    Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
    Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
    J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
    Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
    Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer.
    Chakravarthi BV; Goswami MT; Pathi SS; Robinson AD; Cieślik M; Chandrashekar DS; Agarwal S; Siddiqui J; Daignault S; Carskadon SL; Jing X; Chinnaiyan AM; Kunju LP; Palanisamy N; Varambally S
    Oncogene; 2016 Dec; 35(49):6330-6340. PubMed ID: 27270442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer.
    Cui F; Hu J; Ning S; Tan J; Tang H
    Prostate; 2018 Dec; 78(16):1299-1310. PubMed ID: 30095171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
    Yang Y; Sun P; Xu W; Xia W
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced expression of the DNA glycosylase gene MUTYH is associated with an increased number of somatic mutations via a reduction in the DNA repair capacity in prostate adenocarcinoma.
    Shinmura K; Kato H; Kawanishi Y; Yoshimura K; Igarashi H; Goto M; Tao H; Inoue Y; Sugiyama T; Furuse H; Ozono S; Sugimura H
    Mol Carcinog; 2017 Feb; 56(2):781-788. PubMed ID: 27253753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.
    Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
    Front Immunol; 2022; 13():777724. PubMed ID: 35154101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PVT1 signals an androgen-dependent transcriptional repression program in prostate cancer cells and a set of the repressed genes predicts high-risk tumors.
    Videira A; Beckedorff FC; daSilva LF; Verjovski-Almeida S
    Cell Commun Signal; 2021 Jan; 19(1):5. PubMed ID: 33430890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.